Phase I / II trial of dose adjusted EPOCH chemotherapy with bortezomib combined with integrase inhibitor therapy for HTLV-1 associated T-cell leukemia lymphoma
Crossref DOI link: https://doi.org/10.1186/1742-4690-12-S1-P21
Published Online: 2015-08-28
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Ratner, Lee
Ramos, JC
Noy, Ariela
Barta, Stefan
Parikh, Samir
Phillips, Adrienne
Ambinder, Richard
Rauch, Dan
Harding, John
Baydoun, Hicham
Cheng, Xiaogang
Caruso, Breanna
Jacobson, Steven
Text and Data Mining valid from 2015-08-28
Version of Record valid from 2015-08-28
Article History
First Online: 28 August 2015